The purpose of this research study is to learn more about LGBTQ+/queer college students' experiences with using campus recreation facilities. The information we learn by doing this study may help us develop protocols that help campus recreation facilities provide safe and inclusive spaces for LGBTQ+/queer individuals.

We're investigating the factors that related to driver's trust in navigation systems.

We want to know if members of editorial boards of psychological science journals: (a) are fully aware of the data quality issues associated with careless responding study participants and (b) whether they tend to insist that studies be screened for such data prior to being published in their journals.

To generate information on the undergraduate experience at the University of North Carolina at Chapel Hill from currently enrolled students. This survey is processed every other year.

The purpose of this study is to understand how different amounts of time between seeing similar word pairs affect new learning and later memory for those word pairs (e.g., knee-bone vs. knee-bend).

To test the effectiveness and safety of the drug ravulizumab in patients aged 6-18 years.

The purpose of the HEALEY ALS Platform Trial is to develop and administer various clinical trials under different regimens with ALS to provide multiple treatment options for patients with ALS.

Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades despite numerous attempts to augment standard therapies. Multi-targeted receptor tyrosine kinase inhibitors (MTKIs), such as cabozantinib, can target signaling pathways that are known to be altered in osteosarcoma. Several MTKIs including cabozantinib have recently shown clinical evidence of activity in prospective studies for both pediatric and adult patients with advanced osteosarcoma. Furthermore, feasibility of administering MTKIs in combination with cytotoxic chemotherapy has previously been shown in patients with AML, hepatocellular carcinoma, and soft tissue sarcomas. Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades

Randomized trial testing treatment of ulcerative pyoderma gangrenosum

Mucopolysaccharidosis II (MPS II) or Hunter syndrome, is a rare genetic disorder caused by the decreased levels of a specific enzyme, iduoronate-2-sulfatase. Lack of this enzyme causes buildup of large sugar molecules called glycosaminoglycans (GAGs). The build up of GAGs causes significant damage to the body and brain. This study will evaluate the long-term use of DNL310, an enzyme replacement therapy, to provide the missing enzyme to the body and to break down the stored GAGs. DNL310 uses specific technology to cross the blood brain barrier so that the enzyme can get into the brain. DNL310 is expected to help both the cognitive (brain) and body effects of MPS II. This is an extension study to two current DNL310 clinical trials; only participants currently enrolled in these trials will have the opportunity to participate in this long-term study.